Novartis Faces Board Shake-up Calls After Trial Failures
Shareholder Artisan Partners urges Novartis to overhaul its board and strategy following two major clinical trial setbacks.
Sources
Every article we clustered into this story. Headlines link to the publisher.
- Novartis Needs Board Shakeup and M&A Revamp, Investor Says Bloomberg Markets ·
- The Heart Drug Pelacarsen Fails, Shocking Novartis and Cardiologists The New York Times ·
- STAT+: Pharmalittle: We’re reading about a Novartis investor seeking a shake-up, a Gilead setback, and more STAT
- STAT+: Leukemia drug data suggested a different way to treat diabetes. A new biotech will test that idea STAT
- STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more STAT
- STAT+: Neuromuscular drug from Novartis fails in key study, adding to pressure on company STAT
In this story
- Novartis
- Artisan Partners